Nmp4/CIZ closes the parathyroid hormone anabolic window

Joseph Bidwell, Paul Childress, Marta B. Alvarez, Mark Hood, Yongzheng He, Fredrick Pavalko, Melissa Kacena, Feng Chun Yang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic degenerative diseases are increasing with the aging U.S. population. One consequence of this phenomenon is the need for long-term osteoporosis therapies. Parathyroid hormone (PTH), the only FDA-approved treatment that adds bone to the aged skeleton, loses its potency within two years of initial treatment but the mechanism regulating its limited anabolic window is unknown. We have discovered that disabling the nucleocytoplasmic shuttling transcription factor nuclear matrix protein 4/cas interacting zinc finger protein (Nmp4/CIZ) in mice extends the PTH bone-forming capacity. Nmp4 was discovered during our search for nuclear matrix transcription factors that couple this hormone's impact on osteoblast cytoskeletal and nuclear organization with its anabolic capacity. CIZ was independently discovered as a protein that associates with the focal adhesion-associated mechanosensor p 130Cas. The Nmp4/CIZ-knockout (KO) skeletal phenotype exhibits a modestly enhanced bone mineral density but manifests an exaggerated response to both PTH and to BMP2 and is resistant to disuse-induced bone loss. The cellular basis of the global Nmp4/CIZ-KO skeletal phenotype remains to be elucidated but may involve an expansion of the bone marrow osteoprogenitor population along with modestly enhanced osteoblast and osteoclast activities supporting anabolic bone turnover. As a shuttling Cys2His2 zinc finger protein, Nmp4/CIZ acts as a repressive transcription factor perhaps associated with epigenetic remodeling complexes, but the functional significance of its interaction with p 130Cas is not known. Despite numerous remaining questions, Nmp4/ClZprovides insights into how the anabolic window is regulated, and itself may provide an adjuvant therapy target for the treatment of osteoporosis by extending PTH anabolic efficacy. 2012 Begell House, Inc.

Original languageEnglish
Pages (from-to)205-218
Number of pages14
JournalCritical Reviews in Eukaryotic Gene Expression
Volume22
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Nuclear Matrix-Associated Proteins
Zinc Fingers
Parathyroid Hormone
Proteins
Transcription Factors
Osteoblasts
Bone and Bones
Osteoporosis
Phenotype
Nuclear Matrix
Focal Adhesions
Bone Remodeling
Osteoclasts
Epigenomics
Skeleton
Bone Density
Population
Chronic Disease
Bone Marrow
Organizations

Keywords

  • BMP2
  • Osteoblasts
  • Osteoclast
  • Osteoporosis
  • Osteoprogenitors
  • p130Cas

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Nmp4/CIZ closes the parathyroid hormone anabolic window. / Bidwell, Joseph; Childress, Paul; Alvarez, Marta B.; Hood, Mark; He, Yongzheng; Pavalko, Fredrick; Kacena, Melissa; Yang, Feng Chun.

In: Critical Reviews in Eukaryotic Gene Expression, Vol. 22, No. 3, 2012, p. 205-218.

Research output: Contribution to journalArticle

Bidwell, Joseph ; Childress, Paul ; Alvarez, Marta B. ; Hood, Mark ; He, Yongzheng ; Pavalko, Fredrick ; Kacena, Melissa ; Yang, Feng Chun. / Nmp4/CIZ closes the parathyroid hormone anabolic window. In: Critical Reviews in Eukaryotic Gene Expression. 2012 ; Vol. 22, No. 3. pp. 205-218.
@article{3f7a60c38b9e405597be4f8660f97eae,
title = "Nmp4/CIZ closes the parathyroid hormone anabolic window",
abstract = "Chronic degenerative diseases are increasing with the aging U.S. population. One consequence of this phenomenon is the need for long-term osteoporosis therapies. Parathyroid hormone (PTH), the only FDA-approved treatment that adds bone to the aged skeleton, loses its potency within two years of initial treatment but the mechanism regulating its limited anabolic window is unknown. We have discovered that disabling the nucleocytoplasmic shuttling transcription factor nuclear matrix protein 4/cas interacting zinc finger protein (Nmp4/CIZ) in mice extends the PTH bone-forming capacity. Nmp4 was discovered during our search for nuclear matrix transcription factors that couple this hormone's impact on osteoblast cytoskeletal and nuclear organization with its anabolic capacity. CIZ was independently discovered as a protein that associates with the focal adhesion-associated mechanosensor p 130Cas. The Nmp4/CIZ-knockout (KO) skeletal phenotype exhibits a modestly enhanced bone mineral density but manifests an exaggerated response to both PTH and to BMP2 and is resistant to disuse-induced bone loss. The cellular basis of the global Nmp4/CIZ-KO skeletal phenotype remains to be elucidated but may involve an expansion of the bone marrow osteoprogenitor population along with modestly enhanced osteoblast and osteoclast activities supporting anabolic bone turnover. As a shuttling Cys2His2 zinc finger protein, Nmp4/CIZ acts as a repressive transcription factor perhaps associated with epigenetic remodeling complexes, but the functional significance of its interaction with p 130Cas is not known. Despite numerous remaining questions, Nmp4/ClZprovides insights into how the anabolic window is regulated, and itself may provide an adjuvant therapy target for the treatment of osteoporosis by extending PTH anabolic efficacy. 2012 Begell House, Inc.",
keywords = "BMP2, Osteoblasts, Osteoclast, Osteoporosis, Osteoprogenitors, p130Cas",
author = "Joseph Bidwell and Paul Childress and Alvarez, {Marta B.} and Mark Hood and Yongzheng He and Fredrick Pavalko and Melissa Kacena and Yang, {Feng Chun}",
year = "2012",
doi = "10.1615/CritRevEukarGeneExpr.v22.i3.40",
language = "English",
volume = "22",
pages = "205--218",
journal = "Critical Reviews in Eukaryotic Gene Expression",
issn = "1045-4403",
publisher = "Begell House Inc.",
number = "3",

}

TY - JOUR

T1 - Nmp4/CIZ closes the parathyroid hormone anabolic window

AU - Bidwell, Joseph

AU - Childress, Paul

AU - Alvarez, Marta B.

AU - Hood, Mark

AU - He, Yongzheng

AU - Pavalko, Fredrick

AU - Kacena, Melissa

AU - Yang, Feng Chun

PY - 2012

Y1 - 2012

N2 - Chronic degenerative diseases are increasing with the aging U.S. population. One consequence of this phenomenon is the need for long-term osteoporosis therapies. Parathyroid hormone (PTH), the only FDA-approved treatment that adds bone to the aged skeleton, loses its potency within two years of initial treatment but the mechanism regulating its limited anabolic window is unknown. We have discovered that disabling the nucleocytoplasmic shuttling transcription factor nuclear matrix protein 4/cas interacting zinc finger protein (Nmp4/CIZ) in mice extends the PTH bone-forming capacity. Nmp4 was discovered during our search for nuclear matrix transcription factors that couple this hormone's impact on osteoblast cytoskeletal and nuclear organization with its anabolic capacity. CIZ was independently discovered as a protein that associates with the focal adhesion-associated mechanosensor p 130Cas. The Nmp4/CIZ-knockout (KO) skeletal phenotype exhibits a modestly enhanced bone mineral density but manifests an exaggerated response to both PTH and to BMP2 and is resistant to disuse-induced bone loss. The cellular basis of the global Nmp4/CIZ-KO skeletal phenotype remains to be elucidated but may involve an expansion of the bone marrow osteoprogenitor population along with modestly enhanced osteoblast and osteoclast activities supporting anabolic bone turnover. As a shuttling Cys2His2 zinc finger protein, Nmp4/CIZ acts as a repressive transcription factor perhaps associated with epigenetic remodeling complexes, but the functional significance of its interaction with p 130Cas is not known. Despite numerous remaining questions, Nmp4/ClZprovides insights into how the anabolic window is regulated, and itself may provide an adjuvant therapy target for the treatment of osteoporosis by extending PTH anabolic efficacy. 2012 Begell House, Inc.

AB - Chronic degenerative diseases are increasing with the aging U.S. population. One consequence of this phenomenon is the need for long-term osteoporosis therapies. Parathyroid hormone (PTH), the only FDA-approved treatment that adds bone to the aged skeleton, loses its potency within two years of initial treatment but the mechanism regulating its limited anabolic window is unknown. We have discovered that disabling the nucleocytoplasmic shuttling transcription factor nuclear matrix protein 4/cas interacting zinc finger protein (Nmp4/CIZ) in mice extends the PTH bone-forming capacity. Nmp4 was discovered during our search for nuclear matrix transcription factors that couple this hormone's impact on osteoblast cytoskeletal and nuclear organization with its anabolic capacity. CIZ was independently discovered as a protein that associates with the focal adhesion-associated mechanosensor p 130Cas. The Nmp4/CIZ-knockout (KO) skeletal phenotype exhibits a modestly enhanced bone mineral density but manifests an exaggerated response to both PTH and to BMP2 and is resistant to disuse-induced bone loss. The cellular basis of the global Nmp4/CIZ-KO skeletal phenotype remains to be elucidated but may involve an expansion of the bone marrow osteoprogenitor population along with modestly enhanced osteoblast and osteoclast activities supporting anabolic bone turnover. As a shuttling Cys2His2 zinc finger protein, Nmp4/CIZ acts as a repressive transcription factor perhaps associated with epigenetic remodeling complexes, but the functional significance of its interaction with p 130Cas is not known. Despite numerous remaining questions, Nmp4/ClZprovides insights into how the anabolic window is regulated, and itself may provide an adjuvant therapy target for the treatment of osteoporosis by extending PTH anabolic efficacy. 2012 Begell House, Inc.

KW - BMP2

KW - Osteoblasts

KW - Osteoclast

KW - Osteoporosis

KW - Osteoprogenitors

KW - p130Cas

UR - http://www.scopus.com/inward/record.url?scp=84868600817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868600817&partnerID=8YFLogxK

U2 - 10.1615/CritRevEukarGeneExpr.v22.i3.40

DO - 10.1615/CritRevEukarGeneExpr.v22.i3.40

M3 - Article

C2 - 23140162

AN - SCOPUS:84868600817

VL - 22

SP - 205

EP - 218

JO - Critical Reviews in Eukaryotic Gene Expression

JF - Critical Reviews in Eukaryotic Gene Expression

SN - 1045-4403

IS - 3

ER -